Letter

Possible benefits of low molecular weight heparins

BMJ 1994; 309 doi: 10.1136/bmj.309.6960.1019 (Published 15 October 1994)
Cite this as: BMJ 1994;309:1019.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. L Breimer
  1. Department of Chemical Pathology and Human Metabolism, Royal Free Hospital School of Medicine, London NW3 2QG

    EDITOR, - Consideration of the main end points used in the studies included in A Leizorovicz and colleagues' meta-analysis of the possible merits of low molecular weight heparin1 illustrates certain difficulties in persuading the uninitiated of the validity of this form of pooled analysis of different groups' data. The three studies that used clinical end points (the authors' references 30, 32, and 34) account for more than …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular